Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2019 Jan 18

PMID 30652059

Citations 6

Authors

Justine R Smith

Jacob Peer

Rubens N Belfort

Fatima Cardoso

Richard D Carvajal

Carlos Carvalho

Sarah E Coupland

Laurence Desjardins

Jasmine H Francis

Brenda L Gallie

Dan S Gombos

Hans E Grossniklaus

Steffen Heegaard

Martine J Jager

Swathi Kaliki

Bruce R Ksander

Markus Maeurer

Eduardo Moreno

Jose S Pulido

Bettina Ryll

Arun D Singh

Junyang Zhao

Antonio Parreira

David J Wilson

Joan M OBrien

Affiliations

Soon will be listed here.

Abstract

The 2018 Ocular Oncogenesis and Oncology Conference was held through a partnership of the Association for Research in Vision and Ophthalmology (ARVO) and the Champalimaud Foundation. Twenty-one experts from international ocular oncology centers, from the Champalimaud Clinical Centre and the Champalimaud Foundation Cancer Research Program, and from patient advocacy organizations, delivered lectures on subjects that ranged from global ocular oncology, to basic research in mechanisms of ocular malignancy, to clinical research in ocular cancers, and to anticipated future developments in the area. The scientific program of the conference covered a broad range of ocular tumors-including uveal melanoma, retinoblastoma, ocular surface tumors, and adnexal and intraocular lymphomas-and pathogenesis and management were deliberated in the context of the broader systemic cancer discipline. In considering the latest basic and clinical research developments in ocular oncogenesis and oncology, and providing the opportunity for cross-talk between ocular cancer biologists, systemic cancer biologists, ocular oncologists, systemic oncologists, patients, and patient advocates, the forum generated new knowledge and novel insights for the field. This report summarizes the content of the invited talks at the 2018 ARVO-Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.

Citing Articles

Characterization of international partnerships in global retinoblastoma care and research: A network analysis.

Girdler H, Flegg K, Prochaska J, Dimaras H PLOS Glob Public Health. 2023; 1(12):e0000125.

PMID: 36962140 PMC: 10021644. DOI: 10.1371/journal.pgph.0000125.

Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.

Jiang T, Gu J, Liu S, Chang Q BMC Ophthalmol. 2022; 22(1):375.

PMID: 36127675 PMC: 9487031. DOI: 10.1186/s12886-022-02604-7.

Primary central nervous system lymphoma: Inter-compartmental progression.

Raval V, Binkley E, Aronow M, Valenzuela J, Peereboom D, Wei W EJHaem. 2022; 3(2):362-370.

PMID: 35846050 PMC: 9175875. DOI: 10.1002/jha2.303.

Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.

Kase S, Namba K, Iwata D, Mizuuchi K, Ito T, Hase K Cancer Diagn Progn. 2022; 1(2):69-75.

PMID: 35403133 PMC: 8962760. DOI: 10.21873/cdp.10010.

Vitreoretinal Lymphoma.

Sobolewska B, Chee S, Zaguia F, Goldstein D, Smith J, Fend F Cancers (Basel). 2021; 13(16).

PMID: 34439078 PMC: 8394064. DOI: 10.3390/cancers13163921.

References

Landreville S, Agapova O, Matatall K, Kneass Z, Onken M, Lee R . Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2011; 18(2):408-16. PMC: 3261307. DOI: 10.1158/1078-0432.CCR-11-0946. View

Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M . High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015; 126(1):76-9. DOI: 10.1182/blood-2015-01-620518. View

Chiu H, Dimaras H, Downie R, Gallie B . Breaking down barriers to communicating complex retinoblastoma information: can graphics be the solution?. Can J Ophthalmol. 2015; 50(3):230-5. DOI: 10.1016/j.jcjo.2015.02.003. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Turajlic S, Larkin J . Immunotherapy for Melanoma Metastatic to the Brain. N Engl J Med. 2018; 379(8):789-790. DOI: 10.1056/NEJMe1807752. View

Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B . Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011; 29(7):845-51. DOI: 10.1200/JCO.2010.32.5332. View

Vidoris A, Maia A, Lowen M, Morales M, Isenberg J, Fernandes B . Outcomes of primary endoresection for choroidal melanoma. Int J Retina Vitreous. 2017; 3:42. PMC: 5674241. DOI: 10.1186/s40942-017-0096-5. View

Singh A, Turell M, Topham A . Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881-5. DOI: 10.1016/j.ophtha.2011.01.040. View

Kaliki S, Mohammad F, Tahiliani P, Sangwan V . Concomitant Simple Limbal Epithelial Transplantation After Surgical Excision of Ocular Surface Squamous Neoplasia. Am J Ophthalmol. 2016; 174:68-75. DOI: 10.1016/j.ajo.2016.10.021. View

10.

Postmus D, Mavris M, Hillege H, Salmonson T, Ryll B, Plate A . Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther. 2015; 99(5):548-54. DOI: 10.1002/cpt.332. View

11.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

12.

Medina Mendez C, Ma P, Singh A . Acquired trichomegaly: trichomegaly secondary to erlotinib. JAMA Ophthalmol. 2014; 132(9):1051. DOI: 10.1001/jamaophthalmol.2014.545. View

13.

Sjo L, Heegaard S, Prause J, Petersen B, Pedersen S, Ralfkiaer E . Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics. Invest Ophthalmol Vis Sci. 2008; 50(2):516-22. DOI: 10.1167/iovs.08-2539. View

14.

Francis J, Levin A, Zabor E, Gobin Y, Abramson D . Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. PLoS One. 2018; 13(5):e0197081. PMC: 5965845. DOI: 10.1371/journal.pone.0197081. View

15.

Singh A, Rennie I, Kivela T, Seregard S, Grossniklaus H . The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004; 88(7):962-7. PMC: 1772246. DOI: 10.1136/bjo.2003.029058. View

16.

Araujo I, Coupland S . Primary Vitreoretinal Lymphoma -- A Review. Asia Pac J Ophthalmol (Phila). 2017; 6(3):283-289. DOI: 10.22608/APO.2017150. View

17.

Belfort Neto R, Isenberg J, Castillejos A, SantAna R, Romano A . Novel treatment of papillomatous conjunctival lesions using pattern scanning laser photocoagulation: 1-Year results. Ocul Surf. 2018; 16(3):337-340. DOI: 10.1016/j.jtos.2018.04.004. View

18.

Carvajal R, Sosman J, Quevedo J, Milhem M, Joshua A, Kudchadkar R . Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311(23):2397-405. PMC: 4249701. DOI: 10.1001/jama.2014.6096. View

19.

Liu Z, Meng Q, Bartek Jr J, Poiret T, Persson O, Rane L . Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology. 2017; 6(2):e1252894. PMC: 5353900. DOI: 10.1080/2162402X.2016.1252894. View

20.

ZIMMERMAN L, McLean I . An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol. 1979; 87(6):741-60. DOI: 10.1016/0002-9394(79)90348-9. View